PCSA
Processa Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.06
+0.49%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 301.00 | — | — | — | 874.0K |
| Gross Profit | (301.00) | — | — | — | (874.0K) |
| Operating Expenses | |||||
| R&D Expense | 6.2M | 7.8M | 7.3M | 5.8M | 10.7M |
| SG&A Expense | 6.6M | 6.2M | 4.8M | 5.7M | 8.7M |
| General & Admin Expense | 6.6M | 6.2M | 4.8M | 5.7M | — |
| Selling & Marketing Expense | (301.00) | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 12.9M | 14.0M | 12.1M | 11.5M | 19.4M |
| Cost and Expenses | 12.9M | 14.0M | 12.1M | 11.5M | 20.3M |
| Operating Income (EBIT) | (12.9M) | (14.0M) | (12.1M) | (11.5M) | (20.3M) |
| Non-Operating | |||||
| Interest Income | 101.3K | 109.5K | 201.1K | 335.5K | 101.2K |
| Interest Expense | 2.0K | — | — | — | — |
| Net Interest Income | 99.3K | 109.5K | 201.1K | 335.5K | 101.2K |
| Other Non-Op Income/Expense | (580.1K) | 424.7K | 201.1K | 335.5K | (7.2M) |
| Non-Operating Income (excl Interest) | 578.1K | (424.7K) | (201.1K) | (335.5K) | 7.2M |
| EBT (Pre-Tax Income) | (13.4M) | (13.6M) | (11.9M) | (11.1M) | (27.4M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (13.4M) | (13.6M) | (11.9M) | (11.1M) | (27.4M) |
| Earnings from Cont. Ops | (13.4M) | (13.6M) | (11.9M) | (11.1M) | (27.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (13.4M) | (13.6M) | (11.9M) | (11.1M) | (27.4M) |
| Per Share | |||||
| Basic EPS | ($5.60) | ($10.36) | ($96.75) | ($212.00) | ($851.19) |
| Diluted EPS | ($5.60) | ($10.36) | ($96.75) | ($212.00) | ($851.19) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 2.8M | 1.3M | 122396 | 52463 | 32219 |
| Diluted Shares Outstanding | 2.8M | 1.3M | 122396 | 52463 | 32219 |
| Profitability Metrics | |||||
| EBITDA | (13.4M) | (13.6M) | (11.8M) | (11.1M) | (26.6M) |
| D&A | 1.2K | 1.2K | 782.00 | 222.00 | 788.5K |
| EBIT | (13.4M) | (13.6M) | (11.9M) | (11.1M) | (27.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026